Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of AZD3152 versus AZD7442 for COVID-19 pre-exposure prophylaxis in immunocompromised adults
MOH_2023-08-09_012872Phase 3Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing AZD3152 + placebo with AZD7442 (2 arms). Planned start Aug 2023; status: not yet recruiting.
02
Drugs
sipavibarttixagevimab + cilgavimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on MOH_2023-08-09_012872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-08-09_012872.